Author's response to reviews

Title: ENMD-1198, a novel tubulin-binding agent reduces HIF-1 and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo

Authors:

Christian Moser (christian.moser@klinik.uni-regensburg.de)
Sven A Lang (sven.lang@klinik.uni-regensburg.de)
Akira Mori (akr@kuhp.kyoto-u.ac.jp)
Claus Hellerbrand (claus.hellerbrand@klinik.uni-regensburg.de)
Hans J Schlitt (hans.schlitt@klinik.uni-regensburg.de)
Edward K Geissler (edward.geissler@klinik.uni-regensburg.de)
William E Fogler (fogler@entremed.com)
Oliver Stoeltzing (oliver.stoeltzing@klinik.uni-regensburg.de)

Version: 6 Date: 20 June 2008

Author's response to reviews:

Dear Editorial office team,

again thank you very much for the opportunity to revise our manuscript. We performed the additional experiments (hypoxic conditions) and included these data into the Figure 4 (Fig. 4c and d). However, we again did only detect a minor VEGF-lowering effect of ENMD-1198 in in vitro conditions, as we already had highlighted in our previous version. We therefore speculate that the in vivo effect is more complex and is not well represented by HCC experiments in vitro, a finding which we had observed for other compounds tested in HCC as well.

We hope that this experiment and explanation will be satisfactory for the Editor and Dr. Mabjeesh.

We are looking forward to your final decision and thank for your efforts in handling and reviewing our manuscript.

Kind regards

Oliver Stoeltzing